TRIMTECH Scores $31M in Seed Funding to Combat Neurodegenerative Diseases

TRIMTECH Therapeutics, a Cambridge-based biotech company, has raised $31 million in its oversubscribed seed funding round. The financing was co-led by Cambridge Innovation Capital (CIC) and SV Health Investors' Dementia Discovery Fund (DDF), with additional backing from M Ventures, Pfizer Ventures, and others. This investment will drive the further development of TRIMTECH's pipeline of CNS-penetrant therapeutics, which utilize its innovative TRIMTAC technology to target and degrade protein aggregates associated with neurodegenerative diseases such as Alzheimer's and Huntington's. The company's approach leverages the E3 ubiquitin ligase TRIM21, setting it apart in the field of targeted protein degradation. Established by CIC and DDF alongside academic co-founders from the University of Cambridge, the company aims to address the unmet needs in treating neurodegenerative and inflammatory disorders. Esteemed industry figures have joined its board, including executives from CIC, SV Health, M Ventures, MP Healthcare, and Pfizer Ventures. This funding highlights TRIMTECH’s potential to offer a novel therapeutic route for diseases poorly served by current treatments, marking a significant step forward in drug discovery for neurodegenerative conditions.